11/12/2025 | Press release | Distributed by Public on 11/12/2025 19:12
|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
|
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (Right to Buy) | $1.12 | 11/07/2025 | M(1) | 26,479 | 03/29/2022 | 04/19/2028 | Common Stock | 26,479 | $ 0 | 0 | D | ||||
| Stock Option (Right to Buy) | $4.09 | 11/07/2025 | M(1) | 3,521 | 03/13/2023 | 03/12/2029 | Common Stock | 3,521 | $ 0 | 177,708 | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
|
GOLDSMITH MARK A C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY, CA 94063 |
X | See Remarks | ||
| /s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith | 11/12/2025 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. |
| (2) | Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust. |
| (3) | Includes 193,475 restricted stock units. |
| (4) | This transaction was executed in multiple trades at prices ranging from $60.00 to $60.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| (5) | Represents a transfer to the Jonathan Goldsmith Revocable Trust. |
| (6) | Represents a transfer to the Rebecca Goldsmith Revocable Trust. |
| (7) | Held by Jonathan Goldsmith Revocable Trust. |
| (8) | Reflects the transfer of 4,498 shares. |
| (9) | Held by Rebecca Goldsmith Revocable Trust. |
| (10) | Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. |
| (11) | Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. |
|
Remarks: President and Chief Executive Officer |
|